tradingkey.logo

MaxCyte Inc

MXCT
View Detailed Chart
0.808USD
0.0000.00%
Close 02/06, 16:00ETQuotes delayed by 15 min
86.17MMarket Cap
LossP/E TTM

MaxCyte Inc

0.808
0.0000.00%
Intraday
1m
30m
1h
D
W
M
D

Today

0.00%

5 Days

-10.90%

1 Month

-46.13%

6 Months

-60.39%

Year to Date

-47.87%

1 Year

-81.96%

View Detailed Chart

TradingKey Stock Score of MaxCyte Inc

Currency: USD Updated: 2026-02-06

Key Insights

MaxCyte Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 90 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.64.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

MaxCyte Inc's Score

Industry at a Glance

Industry Ranking
90 / 205
Overall Ranking
240 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

MaxCyte Inc Highlights

StrengthsRisks
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Growing
The company is in a growing phase, with the latest annual income totaling USD 38.63M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 38.63M.
Overvalued
The company’s latest PE is -1.88, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 79.67M shares, decreasing 14.84% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 9.86K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.71.

Analyst Rating

Based on 7 analysts
Buy
Current Rating
5.642
Target Price
+598.27%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

MaxCyte Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

MaxCyte Inc Info

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Ticker SymbolMXCT
CompanyMaxCyte Inc
CEOMasoud (Maher)
Websitehttps://www.maxcyte.com/
KeyAI